Complement inhibition in renal diseases

Nephrology Dialysis Transplantation

Volumn 18, Issue 2, 2003, Pages 237-240

  Inal, Jameel M ^a   Pascual, Manuel ^b   Lesavre, Philippe ^c   Schifferli, Jürg A ^b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Complement; Glomerulonephritis; Ischaemia reperfusion injury

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; MENINGOCOCCUS VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STEROID; TACROLIMUS;

BLOOD GROUP AB; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DISEASE COURSE; EDITORIAL; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE COMPLEX DISEASE; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION SENSITIVITY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MENINGOCOCCOSIS; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REPERFUSION INJURY;

COMPLEMENT INACTIVATOR PROTEINS; DISEASE PROGRESSION; GLOMERULONEPHRITIS; HUMANS; KIDNEY DISEASES; RENAL CIRCULATION; REPERFUSION INJURY;

EID: 0037315004     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/18.2.237     Document Type: Editorial

References (29)

1. Remuzzi G, Ruggenenti P, Codazzi D et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002; 359: 1671-1672
2. Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med 1991; 173: 1083-1089
3. Schifferli JA, Ng YC, Estreicher J, Walport MJ. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J Immunol 1988; 140: 899-904
4. Mitchell DA, Taylor PR, Cook HT et al. Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol 1999; 162: 5675-5679
5. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998; 188: 2313-2320
6. Levy M, Halbwachs-Mecarelli L, Gubler MC et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30: 949-956
7. Hogasen K, Jansen JH. Porcine membranoproliferative glomerulonephritis (MPGN) type II is prevented and reversed by factor H substitution therapy. Mol Immunol 1999; 36: 305
8. Sheerin NS, Springall T, Abe K, Sacks SH. Protection and injury: the differing roles of complement in the development of glomerular injury. Eur J Immunol 2001; 31: 1255-1260
9. Robson MG, Cook HT, Botto M et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001; 166: 6820-6828
10. Bartolotti SR, Peters DK. Delayed removal of renal-bound antigen in decomplemented rabbits with acute serum sickness. Clin Exp Immunol 1978; 32: 199-206
11. Furness PN, Turner DR. Chronic serum sickness glomerulonephritis: removal of glomerular antigen and electron-dense deposits is largely dependent on plasma complement. Clin Exp Immunol 1988; 74: 126-130
12. Rehrig S, Fleming SD, Anderson J et al. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/ reperfusion injury in mice. J Immunol 2001; 167: 5921-5927
13. Park P, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ. Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol Renal Physiol 2002; 282: F352-F357
14. Zhou W, Farrar CA, Abe K et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363-1371
15. Park P, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol 2001; 12: 1383-1390
16. Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787
17. Baid S, Saidman SL, Tolkoff-Rubin N et al. Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol 2001; 13: 577-581
18. Crespo M, Pascual M, Tolkoff-Rubin N. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658
19. Pascual M, Saidman S, Tolkoff-Rubin N et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460-1464
20. Roos A, Nauta AJ, Broers D et al. Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol 2001; 167: 7052-7059
21. Inal JM, Schifferli JA. Complement C2 receptor inhibitor trispanning and the β-chain of C4 share a binding site for complement C2. J Immunol 2002; 168: 5213-5221
22. Matsjo S, Morita Y, Mizuno M, Nishikawa K, Yuzawa Y. The role of complement in the progression of renal fibrosis: a clinical study. Nephrol Dial Transplant 2000; 15: 53-54
23. Raij L, Dalmasso AP, Staley NA, Fish AJ. Renal injury in DOCA-salt hypertensive C5-sufficient and C5-deficient mice. Kidney Int 1989; 36: 582-592
24. Rosenberg ME, Girton R, Finkel D et al. Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol Cell Biol 2002; 22: 1893-1902
25. Moll S, Menoud PA, French L et al. Tubular up-regulation of clusterin mRNA in murine lupus-like nephritis. Am J Pathol 1998; 152: 953-962
26. Wehrli P, Charnay Y, Vallet P et al. Inhibition of post-ischemic brain injury by clusterin overexpression. Nat Med 2001; 7: 977-978
27. Yamada K, Hori Y, Hanafusa N et al. Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Int 2001; 59: 137-146
28. Thomas TC, Rollins SA, Rother RP et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33: 1389-1401
29. Kirschfink M. Targeting complement in therapy. Immunol Rev 2001; 180: 177-189